Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Rhea-AI Summary

Recursion (NASDAQ: RXRX), a clinical-stage TechBio company, provided updates on their pipeline and partnerships during the Download Day event on June 24, 2024. The company expects seven significant clinical trial readouts within the next 18 months. These include Phase 2 data for REC-994 in September 2024, REC-2282 in Q4 2024, REC-4881 for two conditions in H1 2025, REC-3964 by end of 2025, RBM39 with a series of milestones from Q3 2024 to end 2025, and Target Epsilon by end 2025.

Recursion also announced that Bayer would be the first beta-user of their LOWE workflow software, marking a significant step in their collaborative efforts. Additionally, they initiated a joint oncology project and are on track to deliver 25 data packages by Q3 2024. The company has also achieved industrial-scale advancements in ADME processes and genomic mapping, with a 90% success rate in predicting compound outcomes in certain experiments.

Positive

• Seven clinical trial readouts expected within 18 months, indicating robust pipeline progression.
• Bayer becomes first beta-user of LOWE software, enhancing collaborative research.
• Initiation of a joint oncology project with Bayer, expected to advance rapidly.
• On track to deliver 25 data packages to Bayer by Q3 2024.
• Achieved 90 times lab throughput in ADME processes over manual methods.
• Achieved 90% success rate in predicting compound outcomes in specific internal tests.

Negative

• REC-3964 for Clostridioides difficile Infection will only start Phase 2 study in Q4 2024, with data by end 2025, indicating a longer wait for results.
• Target Epsilon (Fibrotic Diseases) will only see Phase 1 data by the end of 2025, indicating a slower timeline for potential market entry.

Insights

Financial Analyst

Recursion's announcement of seven clinical trial readouts within approximately 18 months is significant for retail investors. Clinical trials directly impact a biotech's financial health by potentially increasing future revenue streams. Investors should note that if these trials are successful, Recursion could see substantial gains. Importantly, these readouts span a variety of diseases, including Neurofibromatosis Type 2 and Advanced AXIN1/APC-Mutant Cancers, diversifying potential revenue sources. However, clinical trials are inherently risky. Not all trials lead to marketable drugs and failures could negatively impact stock prices. It's important to monitor upcoming Phase 2 and Phase 1/2 readouts closely as they will provide more concrete data on potential efficacy and safety.

Pharmaceutical Expert

The partnership with Bayer highlights Recursion's strength in collaborative efforts and innovation in drug discovery. Bayer's role as the first beta-user of the LOWE LLM-orchestrated workflow engine is particularly noteworthy. This integration could streamline the drug discovery process, potentially leading to faster development timelines and reduced costs. Additionally, the initiation of the first joint oncology project and the rapid advancement towards Lead Series nomination underline potential high-value therapeutic developments. Yet, the success of this software and the oncology project will depend on precise implementation and real-world efficacy, which remains to be seen.

Tech Expert

The utilization of AI/ML through the LOWE (LLM-Orchestrated Workflow Engine) demonstrates Recursion's commitment to leveraging cutting-edge technology in drug discovery. Such tools enhance the capability of predicting compound efficacy, reducing the trial-and-error cycle traditionally seen in pharmaceutical research. The claim of achieving an estimated 90 times the lab throughput over a manual approach is quite remarkable, suggesting that Recursion could significantly improve its R&D efficiency. Investors should keep an eye on how well these technological advancements translate into tangible drug development successes as it could revolutionize the industry standard.

• Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination
• Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion’s investor and R&D day, on Monday, June 24, 2024.

“Since our last Download Day, which was approximately 18 months ago, we have seen various industries increasingly embrace AI/ML solutions. This adoption has also played out in the drug discovery space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “Over the past decade, we have created a strong leadership position by building the technological and operational capabilities of our platform in order to expand and advance our internal pipeline as well as deliver for our external partners through the integrated use of data, compute, and automation. We look forward to highlighting the various aspects of the Recursion value proposition at Download Day.”

The event will feature a number of prominent speakers, including Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D., Ph.D., UT Southwestern Distinguished Chair in Biomedical Science, and John Marioni, Ph.D., Senior VP and Head of Computational Sciences at Genentech.

Updated pipeline guidance:

• Seven Clinical Trial Readouts expected within approximately 18 months:
  • REC-994 Cerebral Cavernous Malformation—topline Phase 2 data readout in September 2024;
  • REC-2282 Neurofibromatosis Type 2—preliminary Phase 2 data readout in the fourth quarter of 2024;
  • REC-4881 Familial Adenomatous Polyposis—preliminary Phase 2 data readout in the first half of 2025;
  • REC-4881 Advanced AXIN1/APC-Mutant Cancers—preliminary Phase 2 data readout in the first half of 2025;
  • REC-3964 Clostridioides difficile Infection—Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025;
  • RBM39 Advanced HR-Proficient Cancers—IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025;
  • Target Epsilon (Fibrotic Diseases)—IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025.
• Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline.
  

Partnership updates

• Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory, and intuitive research environment for scientists on both sides.
• Additional updates pertaining to the Bayer partnership include:
  • We initiated our first joint oncology project which is now expected to advance rapidly towards Lead Series nomination; and
  • We are on track to complete 25 unique multi-modal data packages that we expect to deliver in the third quarter of 2024.

Platform updates

• ADME industrialization: potential to achieve an estimated 90 times the amount of lab throughput over a manual approach.
• Built our first genome-scale transcriptomics knockout map.
• Multimodal mapping has enabled us in certain experiments to achieve 90% success on our ability to predict compounds that failed later disease-relevant assays in internal tests and 60% ability to predict compounds that passed later disease-relevant assays in internal tests.
• Helix partnership brings hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.

About Recursion
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operation System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating what Recursion believes is one of the fastest supercomputers deployed in the sector, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, Recursion’s anticipated Download Day presentations; Recursion’s ability to decode biology and industrialize drug discovery; the technological and operational capabilities of Recursion’s platform; advancement of Recursion’s internal pipeline and the ability to deliver for its external partners; the advancement of a joint oncology project rapidly towards Lead Series nomination; Bayer becoming the first external beta-user of LOWE and integrating software across the collaboration; the timing for completing 25 unique multi-modal data packages; the timing of IND submissions, clinical trial initiations, and clinical trial readouts; realizing dozens of LLM and causal model driven programs entering the Recursion pipeline; the performance expectations for Recursion’s platform, including 90x of lab throughput over a manual approach, building Recursion’s first genome-scale transcriptomics knockout and multimodal mapping expected capabilities and achievements; Recursion’s continuous expansion of datasets and advancement of the future of medicine; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

FAQ

What clinical trial readouts is Recursion (RXRX) expecting within the next 18 months?

Recursion is expecting seven clinical trial readouts, including REC-994 in September 2024, REC-2282 in Q4 2024, REC-4881 for two conditions in H1 2025, REC-3964 by end of 2025, RBM39 with milestones from Q3 2024 to end 2025, and Target Epsilon by end 2025.

What is the significance of Bayer's involvement with Recursion's LOWE software?

Bayer will be the first beta-user of Recursion's LOWE software, enhancing collaborative drug discovery and development.

What progress has Recursion (RXRX) made in their partnership with Bayer?

Recursion has initiated their first joint oncology project with Bayer, expected to advance rapidly, and is on track to deliver 25 data packages by Q3 2024.

What advancements has Recursion (RXRX) made in their ADME processes?

Recursion has achieved industrial-scale advancements in ADME processes, resulting in 90 times the lab throughput over manual methods.

How successful has Recursion (RXRX) been in predicting compound outcomes?

Recursion has achieved a 90% success rate in predicting compounds that failed later disease-relevant assays and a 60% success rate in predicting those that passed in specific internal tests.